

### **Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application.

### **Listing of Claims:**

What is claimed is:

1. (Currently Amended) A method of treating a vascular disease ~~characterized by~~ resulting from nitric oxide insufficiency in a patient in need thereof comprising administering a therapeutically effective amount of at least one nitrosated angiotensin-converting enzyme inhibitor, wherein the nitrosated angiotensin-converting enzyme inhibitor is a nitrosated alacepril, a nitrosated benazepril, a nitrosated captopril, a nitrosated ceronapril, a nitrosated cilazapril, a nitrosated delapril, a nitrosated duinapril, a nitrosated enalapril, a nitrosated enalaprilat, a nitrosated fosinopril, a nitrosated imidapril, a nitrosated lisinopril, a nitrosated moveltipril, a nitrosated naphthopidil, a nitrosated pentopril, a nitrosated perindopril, a nitrosated quinapril, a nitrosated ramipril, a nitrosated rentipril, a nitrosated spirapril, a nitrosated temocapril, a nitrosatedtrandolapril, a nitrosated urapidil or a nitrosated zofenopril.

2. (Original) The method of claim 1, further comprising administering a pharmaceutically acceptable carrier.

3. (Currently Amended) The method of claim 1, wherein the vascular disease ~~characterized by~~ resulting from nitric oxide insufficiency is ~~a cardiovascular disease; a disease resulting from oxidative stress; low-renin hypertension; salt-sensitive hypertension; low-renin, salt-sensitive hypertension; primary pulmonary hypertension; thromboembolic pulmonary hypertension; pregnancy-induced hypertension; renovascular hypertension; hypertension-dependent end-stage renal disease; heart failure; microvascular cardiac ischemia; left ventricular hypertrophy with disproportionate microvascularization or diastolic dysfunction.~~

4-5 (Cancelled)

6. (Currently Amended) The method of claim 3, wherein the disease resulting from oxidative stress is ~~atherogenesis, atheromatosis, arteriosclerosis, arteriosclerosis, vascular hypertrophy associated with hypertension, hyperlipoproteinaemia,~~ normal vascular degeneration through aging, parathyroidal reactive hyperplasia, chronic renal disease, a neoplastic disease, an inflammatory disease, a neurological and acute bronchopulmonary disease, tumorigenesis, ischemia-reperfusion syndrome, arthritis or sepsis.

7. (Previously Presented) The method of claim 1, wherein the at least one nitrosated angiotensin-converting enzyme inhibitor, is in the form of a pharmaceutically acceptable salt.

8. (Previously Presented) The method of claim 1, wherein the at least one nitrosated angiotensin-converting enzyme inhibitor, is orally administered as a solid dose.

9. (Original) The method of claim 8, wherein the solid dose is a tablet or a capsule.

10. (Original) The method of claim 9, wherein the tablet is a sustained release tablet or the capsule is a sustained release capsule.

11 – 20 (Cancelled)

21. (Original) The method of claim 1, further comprising administering to the patient a therapeutically effective amount of at least one compound used to treat a cardiovascular disease or a pharmaceutically acceptable salt thereof.

22. (Original) The method of claim 21, wherein the compound used to treat the cardiovascular disease is an angiotensin-converting enzyme inhibitor, a beta-adrenergic blocker, a cholesterol reducer, a calcium channel blocker, an angiotensin II receptor antagonist, an endothelin antagonist, a renin inhibitor, or a mixture of two or more thereof.

23-37 (Cancelled)